orismilast

Small moleculeexperimental

Clinical trial activity

13 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
9
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Mar 1, 2011 (NCT01310049)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

O=C(Cc1c(Cl)c[n+]([O-])cc1Cl)c1ccc(OC(F)F)c2c1OC1(CCS(=O)(=O)CC1)O2
Mol. weight
510.3 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • leo32731
  • leo 32731

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05490316Phase 1Sep 1, 2022Innovent Biologics (Suzhou) Co. Ltd.
NCT05469464Phase 2Jul 11, 2022Union Therapeutics
NCT05190419Phase 2Dec 30, 2021Union Therapeutics
NCT04982432Phase 2Oct 1, 2021Union Therapeutics, University of Copenhagen
NCT03812198Phase 1Jan 22, 2019Leo Pharma
NCT03231124Phase 1Jul 25, 2017Leo Pharma, Richmond Pharmacology
NCT03126578Phase 1May 31, 2017Leo Pharma, Nuvisan Pharma Services
NCT02888236Phase 2Sep 1, 2016Humboldt University, Leo Pharma
NCT02753218Phase 1Apr 1, 2016Leo Pharma
NCT02514694Phase 1Jul 1, 2015Leo Pharma
NCT02496546Phase 1Jul 1, 2015Leo Pharma
NCT02126371Phase 1May 1, 2014Covance, Leo Pharma
NCT01310049Phase 1Mar 1, 2011Covance, Leo Pharma
Showing 13 of 13 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Leo PharmaFor profit9922011
Union TherapeuticsFor profit3212021
CovanceFor profit2012011
Humboldt UniversityAcademic/Hospital1012016
Innovent Biologics (Suzhou) Co. Ltd.For profit1112022
Nuvisan Pharma ServicesFor profit1012017
Richmond PharmacologyFor profit1012017
University of CopenhagenAcademic/Hospital1112021
8 organizations
Page 1 / 1